PIK3CD and neoplasm: Inhibitors targeting the PIK3Cδ subunit of phosphatidylinositol-3-OH kinase (PIK3Cδ), such as CAL-101, have been effective in reducing tumor growth in breast cancer models (Glabman et al., 2022; Naito et al., 2024).